FDA Grants R-Tech Ueno IND Approval for Dry Eye Treatment

R-Tech Ueno, Japanese pharmaceutical company, has filed for and received FDA IND approval to begin Phase I and II clinical trials of its severe dry eye treatment, RU -101.

Advertisement
Carrie Pallardy

Ophthalmic solution RU-101 contains the serum component albumin, which has shown to aid in the production of tears.

R-Tech Ueno hopes to gain marketing approval for the treatment soon.

More Articles on Ophthalmology:
Pharm, Olam, InSite Vision Complete Phase 3 Clinical Study
Study Finds 65% of Liver Transplant Patients Develop AMD
Glaucoma Management Lens to be Presented at ARVO 2013

20 criteria hospital leaders should use to evaluate telepsychiatry

Recommended Whitepaper

Advertisement

Next Up in Ophthalmology

  • Montana physician practice acquired 

    Southlake, Texas-based Retina Consultants of America has acquired Montana Retina Consultants, according to a Feb. 5 news release.  Bozeman-based Montana…

    By: Patsy Newitt

  • Louisiana ophthalmology practice acquired 

    Vision Innovation Partners acquired Ophthalmic Associates of Alexandria (Va.), according to a Feb. 2 press release. Founded in 2010, Ophthalmic…

    By: Patsy Newitt

  • American Board of Ophthalmology names CEO

    The American Board of Ophthalmology has appointed Steven Gedde, MD, as its next CEO.  Dr. Gedde is an ophthalmologist and…

    By: Cameron Cortigiano
Advertisement

Comments are closed.